Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection

Journal of Clinical Virology

Volumn 56, Issue 1, 2013, Pages 13-18

  Martin Gandul C ^a   Perez Romero P ^a   Sanchez M ^a   Bernal, G ^a   Suarez G ^a   Sobrino, M ^a   Merino, L ^a   Cisneros, J M ^a   Cordero, E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

CMV seropositive recipients; Cut off viral load; Cytomegalovirus (CMV); Preemptive therapy; Real time PCR; Solid organ transplantation (SOT)

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DUODENITIS; ENCEPHALITIS; FEMALE; GASTRITIS; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEPATITIS; HUMAN; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VALIDATION PROCESS; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; CLINICAL LABORATORY TECHNIQUES; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; ORGAN TRANSPLANTATION; PLASMA; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84871516782     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.09.017     Document Type: Article

References (40)

1. Cytomegalovirus. Am J Transplant 2004, 4(suppl.):51-58.
2. Baldanti F., Lilleri D., Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 2008, 41:237-241.
3. Sun H.Y., Wagener M.M., Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008, 8:2111-2118.
4. Humar A., Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006, 6:262-274.
5. Kotton C.N., Kumar D., Caliendo A.M., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779-795.
6. Preiksaitis J.K., Brennan D.C., Fishman J., Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005, 5:218-227.
7. Pang X.L., Chui L., Fenton J., LeBlanc B., Preiksaitis J.K. Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol 2003, 41:3167-3174.
8. Gimeno C., Solano C., Latorre J.C., et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008, 46:3311-3318.
9. Choi S.M., Lee D.G., Lim J., et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci 2009, 24:571-578.
10. Guiver M., Fox A.J., Mutton K., et al. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparasion with CMV antigenemia in heart and lung transplant recipients. Transplantation 2001, 71:1609-1615.
11. Sanghavi S.K., Abu-Elmagd K., Keightley M.C., et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol 2008, 42:335-342.
12. Mengelle C., Pasquier C., Rostaing L., et al. Quantitation of human cytomegalovirus in recipients of solid organ transplant by real-time PCR and pp65 antigenemia. J Med Virol 2003, 69:225-231.
13. Espy M.J., Uhl J.R., Sloan L.M., et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev 2006, 19:165-256.
14. Peres R.M., Costa C.R., Andrade P.D., et al. Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cut-off value by real-time PCR. BMC Infect Dis 2010, 10:147.
15. Yakushiji K., Gondo H., Kamezaki K., et al. Monitoring of cytomegalovirus reactivation alter allogeneic stem cell transplantation: comparasion of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant 2002, 29:599-606.
16. Machida U., Kami M., Fukui T., et al. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol 2000, 38:2536-2542.
17. Singh N., Wannstedt C., Keyes L., et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 2008, 14:240-244.
18. Benmarzouk-Hidalgo O.J., Cordero E., Martin-Pena A., et al. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. Antivir Ther 2009, 14:641-647.
19. Sun H.Y., Cacciarelli T.V., Wagener M.M., Singh N. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients. Transpl Immunol 2010, 23:166-169.
20. Humar A., Gregson D., Caliendo A.M., et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999, 68:1305-1311.
21. Weigand K., Schnitzler, Schmidt J., et al. Cytomegalovirus infection after liver transplantation incidence, risk, and benefits of prophylaxis. Transplant Proc 2010, 42:2634-2641.
22. Emery V.C., Asher K., Sanjuan C.D.J. Importance of the cytomegalovirus seropositive recipients as a contributor to disease burden after solid organ transplantation. J Clin Virol 2012, 54:125-129.
23. Pang X.L., Fox J.D., Fenton J.M., Miller G.G., Caliendo A.M., Preiksaitis J.K. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9:258-268.
24. Li H., Dummer J.S., Estes W.R., Meng S., Wright P.F., Tang Y.W. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol 2003, 41:187-191.
25. Kalpoe J.S., Kroes A.C., de Jong M.D., et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004, 42:1498-1504.
26. Hadaya K., Wunderli W., Deffernez C., et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol 2003, 41:3757-3764.
27. Hardinger K.L., Rasu R.S., Skelton R., Miller B.W., Brennan D.C. Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days?. J Transplant 2010, 957549.
28. Portela D., Patel R., Larson-Keller J.J., et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995, 17:1014-1018.
29. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
30. de la Torre-Cisneros J., Farinas M.C., Caston J.J., et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011, 29:735-758.
31. Lisboa L.F., Asberg A., Kumar D., et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011, 91:231-236.
32. Levitsky J., Freifeld A.G., Puumala S., et al. Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?. Clin Transplant 2008, 22:222-228.
33. Ruell J., Barnes C., Mutton K., et al. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant 2007, 40:55-61.
34. Eid A.J., Arthurs S.K., Deziel P.J., Wilhelm M.P., Razonable R.R. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010, 10:157-161.
35. Jang E.Y., Park S.Y., Lee E.J., et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis 2009, 48:121-124.
36. Grim S.A., Pereira E., Guzman G., Clark N.M. CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation 2010, 90:799-801.
37. Benmarzouk-Hidalgo O.J., Cisneros J.M., Cordero E., et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 2011, 91:927-933.
38. Egli A., Binet I., Binggeli S., et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008, 6:29.
39. Rowshani A.T., Bemelman F.J., van Leeuwen E.M., van Lier R.A., Ten Berge I.J. Clinical and inmunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005, 79:381-386.
40. Cantisan S., Solana R., Lara R., et al. CD45RA expression on HCMV-specific effector memory CD8+ T cells is associated with the duration and intensity of HCMV replication after transplantation. Clin Immunol 2010, 137:81-88.